TY - JOUR
T1 - Quantifying the altered cardiac response to atropine following pyridostigmine in rhesus macaques
AU - Birnbaum, Shari G.
AU - Richardson, Bruce C.
AU - Dellinger, John A.
N1 - Funding Information:
Suspected anti-ChE exposures are generally confirmed by an assay for blood cholinesterase (ChE) activity, although the detection of anti-ChE exposures using blood ChE activity has several disadvantages. Normal thE values can vary substantially between species (13,20), within a population, between sexes (25) and within one individual across time (26,27). These variabilities necessitate a recent baseline ChE activity level for each individual before a meaningful diagnosis can be obtained. In addition, the relationship between blood ChE levels and clinical symptoms is equivocal. Although inhibition of normal enzyme activity by approx- 1This research was supported by the U.S. Air Force under a subcontract from the University of Utah, Utah Consortium for Research and Education, contract number 433615-83-D0603, Task 18. The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Air Force position, policy, or decision, unless so designated by other documentation. The care and use of the animals in this study conformed to treatment methods as described in the "Guide for the Care and the Use of Laboratory Animals," Institute of Laboratory Animal Resources, National Research Council.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1988/10
Y1 - 1988/10
N2 - An estimate of the amplitude of respiratory sinus arrhythmia (V̂) has been proposed as a noninvasive measure of parasympathetic activity. This experiment monitored V̂ in response to a subclinical dose of pyridostigmine bromide (PYR) and a pharmacological challenge of atropine sulfate (ATR). Twelve male rhesus macaques received 200 μg/kg of PYR 30 min prior to an injection of 0, 14, 44, or 140 μg/kg ATR. The decrease in V̂ after both the 44 and 140 μg/kg ATR doses was similar to the response to ATR alone in a previous experiment. The 14 μg/kg dose of ATR did not significantly decrease V̂ in this experiment, which is in contrast with the large decrease of V̂ after ATR alone in a previous experiment. Neither drug affected respiration. The dose of ATR which would be effective in causing a 30% decrease of V̂ in the presence of PYR was estimated to be 18.3 μg/kg of ATR. This is twice the dose of ATR calculated to have the same effect without PYR. The attenuated response of V̂ after a pharmacological challenge of ATR may be used to quantify the latent muscarinic effects from exposure to anticholinesterase agents. The attenuated response to ATR may also be useful for evaluating the return of normal cholinergic function after disruption by cholinesterase inhibitors.
AB - An estimate of the amplitude of respiratory sinus arrhythmia (V̂) has been proposed as a noninvasive measure of parasympathetic activity. This experiment monitored V̂ in response to a subclinical dose of pyridostigmine bromide (PYR) and a pharmacological challenge of atropine sulfate (ATR). Twelve male rhesus macaques received 200 μg/kg of PYR 30 min prior to an injection of 0, 14, 44, or 140 μg/kg ATR. The decrease in V̂ after both the 44 and 140 μg/kg ATR doses was similar to the response to ATR alone in a previous experiment. The 14 μg/kg dose of ATR did not significantly decrease V̂ in this experiment, which is in contrast with the large decrease of V̂ after ATR alone in a previous experiment. Neither drug affected respiration. The dose of ATR which would be effective in causing a 30% decrease of V̂ in the presence of PYR was estimated to be 18.3 μg/kg of ATR. This is twice the dose of ATR calculated to have the same effect without PYR. The attenuated response of V̂ after a pharmacological challenge of ATR may be used to quantify the latent muscarinic effects from exposure to anticholinesterase agents. The attenuated response to ATR may also be useful for evaluating the return of normal cholinergic function after disruption by cholinesterase inhibitors.
KW - Anticholinesterase
KW - Pharmacological challenge
KW - Respiratory sinus arrhythmia
UR - http://www.scopus.com/inward/record.url?scp=0024153126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024153126&partnerID=8YFLogxK
U2 - 10.1016/0091-3057(88)90362-0
DO - 10.1016/0091-3057(88)90362-0
M3 - Article
C2 - 3244715
AN - SCOPUS:0024153126
SN - 0091-3057
VL - 31
SP - 381
EP - 386
JO - Pharmacology, Biochemistry and Behavior
JF - Pharmacology, Biochemistry and Behavior
IS - 2
ER -